GSK3B and melanoma: Interestingly, a recent study showed that the inhibition of glycogen synthase kinase-3 beta (GSK3β) decreases the expression of PD-1 on CD8+ T cells and is as effective as anti-PD-1/anti-PD-L1 antibodies for controlling B16F10 melanoma [15].